Primary therapy of Waldenström macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): Long-term results of a phase 2 study of the European Myeloma Network (EMN)

Blood

Volumn 122, Issue 19, 2013, Pages 3276-3282

  Dimopoulos, Meletios A ^a   Garćia Sanz, Ramón ^b   Gavriatopoulou, Maria ^a   Morel, Pierre ^c   Kyrtsonis, Marie Christine ^a   Michalis, Eurydiki ^d   Kartasis, Zafiris ^e   Leleu, Xavier ^f   Palladini, Giovanni ^g   Tedeschi, Alessandra ^h   Gika, Dimitra ^a   Merlini, Giampaolo ^g   Kastritis, Efstathios ^a   Sonneveld, Pieter ⁱ  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^c Hopital Schaffner   (France)

^d G GENNIMATAS GENERAL HOSPITAL   (Greece)

^e General Hospital of Chalkida   (Greece)

^f LILLE UNIVERSITY HOSPITAL   (France)

^g UNIVERSITY OF PAVIA   (Italy)

^h OSPEDALE NIGUARDA CA GRANDA   (Italy)

ⁱ ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BENDAMUSTINE; BETA 2 MICROGLOBULIN; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; IMMUNOGLOBULIN M; PREDNISONE; RITUXIMAB; SERUM ALBUMIN; VINCRISTINE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; MONOCLONAL ANTIBODY; PYRAZINE DERIVATIVE;

ADULT; AGE; AGED; ALBUMIN BLOOD LEVEL; ANEMIA; ARTICLE; BLOOD VISCOSITY; CARDIOVASCULAR DISEASE; CONSTIPATION; DIARRHEA; DISEASE COURSE; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; FOLLOW UP; HUMAN; HYPOTENSION; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LOW DRUG DOSE; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHIC PAIN; NEUROPATHY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SPLENOMEGALY; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; WALDENSTROEM MACROGLOBULINEMIA; WEIGHT REDUCTION; BLOOD; DRUG ADMINISTRATION; MIDDLE AGED; MORTALITY; PATHOLOGY; SURVIVAL; TREATMENT OUTCOME; VERY ELDERLY; CLINICAL TRIAL; PERIPHERAL NERVOUS SYSTEM DISEASES; WALDENSTROM MACROGLOBULINEMIA;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DEXAMETHASONE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOGLOBULIN M; MALE; MIDDLE AGED; PERIPHERAL NERVOUS SYSTEM DISEASES; PYRAZINES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; WALDENSTROM MACROGLOBULINEMIA;

EID: 84888260930     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-05-503862     Document Type: Article

References (36)

1. Dimopoulos MA, Kyle RA, Anagnostopoulos A, Treon SP. Diagnosis and management of Waldenström's macroglobulinemia. J Clin Oncol. 2005;23(7):1564-1577.
2. Vijay A, Gertz MA. Waldenströ m macroglobulinemia. Blood. 2007;109(12):5096-5103.
3. Dimopoulos MA, Zervas C, Zomas A, et al. Treatment of Waldenström's macroglobulinemia with rituximab. J Clin Oncol. 2002;20(9):2327-2333.
4. Dimopoulos MA, Zervas C, Zomas A, et al. Extended rituximab therapy for previously untreated patients with Waldenströ m's macroglobulinemia. Clin Lymphoma. 2002;3(3):163-166.
5. Dimopoulos MA, Anagnostopoulos A, Zervas C, et al. Predictive factors for response to rituximab in Waldenström's macroglobulinemia. Clin Lymphoma. 2005;5(4):270-272.
6. Gertz MA, Rue M, Blood E, Kaminer LS, Vesole DH, Greipp PR. Multicenter phase 2 trial of rituximab for Waldenström macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma. 2004;45(10):2047-2055.
7. Ghobrial IM, Fonseca R, Greipp PR, et al; Eastern Cooperative Oncology Group. Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenström macroglobulinemia: an Eastern Cooperative Oncology Group Study. Cancer. 2004;101(11):2593-2598.
8. Treon SP, Branagan AR, Hunter Z, Santos D, Tournhilac O, Anderson KC. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenström's macroglobulinemia. Ann Oncol. 2004;15(10):1481-1483.
9. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol. 2007;25(22):3344-3349.
10. Tedeschi A, Benevolo G, Varettoni M, et al. Fludarabine plus cyclophosphamide and rituximab in Waldenström macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease. Cancer. 2012;118(2):434-443.
11. Buske C, Hoster E, Dreyling M, et al; German Low-Grade Lymphoma Study Group. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia. 2009;23(1):153-161.
12. Leleu X, Eeckhoute J, Jia X, et al. Targeting NF-kappaB in Waldenstrom macroglobulinemia. Blood. 2008;111(10):5068-5077.
13. Roccaro AM, Leleu X, Sacco A, et al. Dual targeting of the proteasome regulates survival and homing in Waldenströ m macroglobulinemia. Blood. 2008;111(9):4752-4763.
14. Roccaro AM, Sacco A, Aujay M, et al. Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenström macroglobulinemia. Blood. 2010;115(20):4051-4060.
15. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, Castritis E, Bitsaktsis A, Pangalis GA. Treatment of relapsed or refractory Waldenström's macroglobulinemia with bortezomib. Haematologica. 2005;90(12):1655-1658.
16. Chen CI, Kouroukis CT, White D, et al; National Cancer Institute of Canada Clinical Trials Group. Bortezomib is active in patients with untreated or relapsed Waldenström's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25(12):1570-1575.
17. Treon SP, Hunter ZR, Matous J, et al. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenström's macroglobulinemia: results of WMCTG Trial 03-248. Clin Cancer Res. 2007;13(11):3320-3325.
18. Wang M, Han XH, Zhang L, et al. Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leukemia. 2008;22(1):179-185.
19. Alinari L, White VL, Earl CT, et al. Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma. MAbs. 2009;1(1):31-40.
20. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenström's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenström's Macroglobulinemia. Semin Oncol. 2003;30(2):110-115.
21. Kyle RA, Treon SP, Alexanian R, et al. Prognostic markers and criteria to initiate therapy in Waldenström's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenströ m's Macroglobulinemia. Semin Oncol. 2003;30(2):116-120.
22. Kimby E, Treon SP, Anagnostopoulos A, et al. Update on recommendations for assessing response from the Third International Workshop on Waldenström's Macroglobulinemia. Clin Lymphoma Myeloma. 2006;6(5):380-383.
23. Owen RG, Kyle RA, Stone MJ, et al; VIth International Workshop on Waldenströ m macroglobulinaemia. Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop. Br J Haematol. 2013;160(2):171-176.
24. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496-509.
25. Scrucca L, Santucci A, Aversa F. Regression modeling of competing risk using R: an in depth guide for clinicians. Bone Marrow Transplant. 2010;45(9):1388-1395.
26. Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenström macroglobulinemia. Blood. 2009;113(18):4163-4170.
27. Dimopoulos MA, Alexanian R, Gika D, et al. Treatment of Waldenström's macroglobulinemia with rituximab: prognostic factors for response and progression. Leuk Lymphoma. 2004;45(10):2057-2061.
28. Ghobrial IM, Xie W, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström macroglobulinemia. Am J Hematol. 2010;85(9):670-674.
29. Treon SP, Ioakimidis L, Soumerai JD, et al. Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol. 2009;27(23):3830-3835.
30. Treon SP, Yang G, Hanzis C, et al. Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenström macroglobulinaemia. Br J Haematol. 2011;154(2):223-228.
31. Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12(5):431-440.
32. Miyakoshi S, Kami M, Yuji K, et al. Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. Blood. 2006;107(9):3492-3494.
33. Gotoh A, Ohyashiki K, Oshimi K, et al. Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: a questionnaire-based report from the "lung injury by bortezomib" joint committee of the Japanese society of hematology and the Japanese society of clinical hematology. Int J Hematol. 2006;84(5):406-412.
34. Shimazaki C, Kobayashi Y, Inaba T, Taniwaki M. Dexamethasone reduces the risk of bortezomibinduced pulmonary complications in Japanese myeloma patients. Int J Hematol. 2006;84(1):90-91.
35. Zappasodi P, Dore R, Castagnola C, et al. Rapid response to high-dose steroids of severe bortezomib-related pulmonary complication in multiple myeloma. J Clin Oncol. 2007;25(22):3380-3381.
36. Ohri A, Arena FP. Severe pulmonary complications in African-American patient after bortezomib therapy. Am J Ther. 2006;13(6):553-555.